NDIS Funding

Ulysses can be funded through a participant’s NDIS budget if they are self or plan managed

Low cost, low risk Assistive Technology

In Australia, the system can be purchased or leased by end users:

Outright purchase
$1,500 (plus GST) (includes 1 year of complementary software updates)
or
Monthly leasing
$150 (plus GST) per month (for a minimum commitment of 3 months)

Typically a participant can use funding from their Assistive Technology (Low-cost AT - Personal Mobility) or Consumables budget. If you are looking to fund Ulysses via these categories, we can prepare a quote or invoice for you and then depending on the type of NDIS plan you are under, follow the instructions below:

Self managed participants

Contact us to request an invoice, there is no need for justification.

Plan managed participant

Plan managed participants

Contact us to request a quote to submit to your plan manager for approval.

In some cases, you may be required to provide written justification from an Occupational Therapist or allied health professional to your Plan Manager. We have prepared some answers to commonly asked questions below, however please contact us should you or your providers have further questions.

Therapy justification FAQs

The Ulysses therapy system is an ARTG registered (No. 402309), Class I medical device that promotes improved upper limb motor function through encouraging users to perform clinically designed tasks and activities using the latest in Virtual Reality technology. In doing so, the immersive nature of VR and gamified task-reward structure increases therapy engagement and compliance. It is highly compact and portable, suitable to be used in the home with minimal supervision required.

The system comprises a wireless Oculus Meta Quest™ 2 VR headset which has been specifically configured with Neuromersiv’s proprietary software so that no other software can be installed onto the headset. This ensures the system maintains safety as a registered medical device and so that Neuromersiv can remotely install software updates when the headset is connected to Wi-fi.

The Ulysses VR software has been intentionally designed to be operated using the Meta Quest’s hand tracking technology, allowing the user to use their own hands to interact with the virtual environment rather than using handheld controllers, as seen with most head mounted display VR devices. This is beneficial for users with limited grip strength or mild to moderate hand contracture.

The content of the Ulysses VR software has been designed in consultation with therapists to deliver tasks and activities that are not only engaging and challenging but adhere to proven neurorehabilitation therapy principles including the importance of repetition whilst making tasks functional and rewarding.

One aspect of the Ulysses VR software is the virtual Activities of Daily Living (ADL) rooms which invite users to practice tasks that are essential to everyday life in realistic household settings such as a bathroom or kitchen.

The main advantages of practicing these tasks in VR first, instead of going straight to real-world practice include:

Allows confidence to be built, without fear of dropping objects or safety concerns;

Tasks can be gamified, reward-based and scored to provide engagement and motivation when practiced repeatedly.

The Ulysses therapy system is an ARTG registered (No. 402309), Class I medical device that promotes improved upper limb motor function through encouraging users to perform clinically designed tasks and activities using the latest in Virtual Reality technology. In doing so, the immersive nature of VR and gamified task-reward structure increases therapy engagement and compliance. It is highly compact and portable, suitable to be used in the home with minimal supervision required.

The system comprises a wireless Oculus Meta Quest™ 2 VR headset which has been specifically configured with Neuromersiv’s proprietary software so that no other software can be installed onto the headset. This ensures the system maintains safety as a registered medical device and so that Neuromersiv can remotely install software updates when the headset is connected to Wi-fi.

The Ulysses VR software has been intentionally designed to be operated using the Meta Quest’s hand tracking technology, allowing the user to use their own hands to interact with the virtual environment rather than using handheld controllers, as seen with most head mounted display VR devices. This is beneficial for users with limited grip strength or mild to moderate hand contracture.

The content of the Ulysses VR software has been designed in consultation with therapists to deliver tasks and activities that are not only engaging and challenging but adhere to proven neurorehabilitation therapy principles including the importance of repetition whilst making tasks functional and rewarding.

One aspect of the Ulysses VR software is the virtual Activities of Daily Living (ADL) rooms which invite users to practice tasks that are essential to everyday life in realistic household settings such as a bathroom or kitchen.

The main advantages of practicing these tasks in VR first, instead of going straight to real-world practice include:

Allows confidence to be built, without fear of dropping objects or safety concerns;

Tasks can be gamified, reward-based and scored to provide engagement and motivation when practiced repeatedly.

The therapy is currently designed predominantly for adults who have suffered a stroke (ischemic or hemorrhagic) or brain injury (traumatic or acquired) however it may also be beneficial to users with other neurological conditions. We are frequently creating new therapy content to cater for a variety of other conditions and severities of condition.

It is well known that many traditional forms of upper limb rehabilitation therapy are simply boring and disinteresting to patients, leaving them disheartened and unmotivated to comply with their prescribed therapy. Even if patients do comply, it is usually not enough therapy, with one well regarded study by the Australian Physiotherapy Association suggesting at least an extra 240% of rehabilitation was needed for significant likelihood that extra rehabilitation would improve activity for patients after stroke.

The Ulysses VR system is designed as an engaging tool that can be used in conjunction with other therapy modalities in order to increase the dosage of prescribed rehabilitation. Furthermore, the system’s portability combined with the self-guided design of the therapy software removes many of the barriers to achieving greater therapy compliance giving patients more autonomy over when and where they do their rehab.

This guide can also be printed via a downloadable PDF:

Have further questions?

Please call us on 1300 617 671 or email at connect@neuromersiv.com

sn’t VR just for playing games?

No. While VR is commonly associated with gaming, head mounted display VR hardware is becoming increasingly used in a variety of applications, including rehabilitation. In fact, a number of clinical studies and reviews have shown the effectiveness of using specifically-designed VR as part of a stroke rehabilitation protocol (see links below):

1

Sensory Feedback and Interactivity: Enhancing Motivation and Engagement for VR Stroke Rehabilitation. 2021 International Conference on Computer & Information Sciences (ICCOINS), Jul 2021, Kuching, Malaysia.

2

Effect of Specific Over Nonspecific VR-Based Rehabilitation on Poststroke Motor Recovery: A Systematic Meta-analysis. American Society of Neurorehabilitation, Neurorehabilitation and Neural Repair 2019.

3

Enhancing Upper Limb Rehabilitation of Stroke Patients With Virtual Reality: A Mini Review. Frontiers in Virtual Reality, 8 November, 2021.

4

Neuroplasticity and Virtual Reality, Chapter 2, Virtual Reality for Physical and Motor Rehabilitation, Virtual Reality Technologies for Health and Clinical Applications, New York 2014.

This growing clinical evidence points to the positive effect that immersive VR has to promote
neuroplastic changes in the brain due to the increased release of dopamine during use. 

The Ulysses VR therapy system is considered low-cost AT (Assistive Technology). Typically a participant can use funding from their Assistive Technology (Low-cost AT – Personal Mobility) or Consumables budget.

In Australia, the system can be purchased or leased by end users.
Outright purchase – $1,500 (plus GST) (includes 1 year of complementary software updates)
or
Monthly leasing – $150 (plus GST) per month (for a minimum commitment of 3 months)

Request a demo

One of our team members will respond to your enquiry shortly

Request Information pack

One of our team members will respond to your enquiry shortly

Anshul Dayal

Co-Founder & CEO

Anshul has over 10 years experience in leading large technical teams in creating leading edge Hollywood content and software, including being a part of the Academy Award winning team to work on blockbuster film, Happy Feet.

Stephanie Ho

Neuromersiv Ambassador

After surviving a severe stroke at 22 years of age, Stephanie has committed her life to improve the healthcare system and easing the burden for other survivors. She currently serves as an Executive Board Member for NSW Agency for Clinical Innovation and is a regular keynote speaker on the topic of stroke and the impact of rehabilitation from a consumer perspective. Stephanie was awarded for her work in 2019 by the National Stroke Foundation.

Dr Jodie Marquez

Clinical & Research

Jodie is a physiotherapist with 20 years of experience in neuro-rehabilitation. She currently serves as Senior Lecturer at the University of Newcastle and has served as Chief Investigator on a number of funded clinical trial studies.

Professor Michael Nilsson

Rehabilitation Innovation

Michael is the Director of the Centre for Rehab Innovations and Global Innovation Chair of Rehabilitation Medicine at the University of Newcastle. As a senior translational researcher, clinician and leader in Rehabilitation Medicine, he recently established CRI together with an interdisciplinary team of leading researchers and clinicians. CRI engages with industry and public and private healthcare to develop technology-supported solutions for individually-tailored health and rehabilitation programs.

Warren Bingham

Commercialisation & Strategy

Warren is the General Manager of Cicada MedLab and the founder and Executive Chairman of MedTech International. As part of the global executive team to introduce PillCam® to the world, he was instrumental in the company going from startup in 2000 to being sold in 2014 for $1 billion.

Oliver Morton-Evans

Co-Founder & COO

Oliver has 7 years experience in design and project management having run visual effects & VR production studio, pic4 over this time. Prior to this, Oliver served as a digital media producer and designer for global children’s entertainment brand, The Wiggles.